CH713096B1 - Pharmazeutische Zusammensetzung zur Behandlung von Vergiftungen. - Google Patents

Pharmazeutische Zusammensetzung zur Behandlung von Vergiftungen. Download PDF

Info

Publication number
CH713096B1
CH713096B1 CH00475/17A CH4752017A CH713096B1 CH 713096 B1 CH713096 B1 CH 713096B1 CH 00475/17 A CH00475/17 A CH 00475/17A CH 4752017 A CH4752017 A CH 4752017A CH 713096 B1 CH713096 B1 CH 713096B1
Authority
CH
Switzerland
Prior art keywords
solution
chlorine dioxide
ppm
pain
pharmaceutical composition
Prior art date
Application number
CH00475/17A
Other languages
German (de)
English (en)
Inventor
Ludwig Kalcker Andreas
Original Assignee
Schweizer Zentrum Fuer Wss Forschung Innovation Und Entwicklung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweizer Zentrum Fuer Wss Forschung Innovation Und Entwicklung filed Critical Schweizer Zentrum Fuer Wss Forschung Innovation Und Entwicklung
Priority to CH00475/17A priority Critical patent/CH713096B1/de
Priority to PCT/EP2018/059058 priority patent/WO2018185348A1/fr
Publication of CH713096B1 publication Critical patent/CH713096B1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH00475/17A 2017-04-07 2017-04-07 Pharmazeutische Zusammensetzung zur Behandlung von Vergiftungen. CH713096B1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CH00475/17A CH713096B1 (de) 2017-04-07 2017-04-07 Pharmazeutische Zusammensetzung zur Behandlung von Vergiftungen.
PCT/EP2018/059058 WO2018185348A1 (fr) 2017-04-07 2018-04-09 Composition pharmaceutique pour traiter des intoxications aigües

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH00475/17A CH713096B1 (de) 2017-04-07 2017-04-07 Pharmazeutische Zusammensetzung zur Behandlung von Vergiftungen.

Publications (1)

Publication Number Publication Date
CH713096B1 true CH713096B1 (de) 2018-04-30

Family

ID=61972113

Family Applications (1)

Application Number Title Priority Date Filing Date
CH00475/17A CH713096B1 (de) 2017-04-07 2017-04-07 Pharmazeutische Zusammensetzung zur Behandlung von Vergiftungen.

Country Status (2)

Country Link
CH (1) CH713096B1 (fr)
WO (1) WO2018185348A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2002002762A1 (es) * 2002-12-02 2005-01-14 Protecsa S A Proceso para obtener una solucion de dioxido de cloro acuoso.
WO2011086579A1 (fr) * 2010-01-18 2011-07-21 Prophylaxis Procédé de production d'une forme liquide stable et pure de dioxyde de chlore

Also Published As

Publication number Publication date
WO2018185348A1 (fr) 2018-10-11

Similar Documents

Publication Publication Date Title
EP0648114B1 (fr) Liposomes, procede concernant leur fabrication, et leur utilisation dans la fabrication d'un medicament
DE60318237T2 (de) Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol
CH645806A5 (de) Augenheilmittel.
DE2832204A1 (de) Mittel zur behandlung von nervenerkrankungen, verfahren zu seiner herstellung und seine verwendung
EP2348851B1 (fr) Composition comprenant du glucosylglycérol
WO2018185346A1 (fr) Composition pharmaceutique pour le traitement de maladies infectieuses
EP3606505B1 (fr) Composition pour application nasale
DE60104670T2 (de) Verwendung eines lacrophilen Präparats in Augentropfen, die therapeutische Komponenten enthalten
DE202006011920U1 (de) Zusammensetzung zur Behandlung von Rhinitis
EP3285791B1 (fr) Composition pour le traitement de la cavité laryngopharyngée
CH713096B1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Vergiftungen.
EP3285790B1 (fr) Composition pour le traitement de la cavité laryngopharyngée
DE60100666T2 (de) Tierärztliche zusammensetzungen zur behandlung von parasiterkrankungen
DE202006005924U1 (de) Zusammensetzung zur Behandlung von Rhinitis
EP3352763A1 (fr) Substance pour la prophylaxie et le traitement d'infections provoquées par des virus influenza
EP1850913B1 (fr) Substance pour le traitement d'infections
DE202012013584U1 (de) Pharmazeutische Formulierung enthaltend Curcumin
DE2461570C3 (de) Arzneimittel für die Behandlung bakterieller Infektionen der Augen und/oder der Ohren und Verfahren zu ihrer Herstellung
DE3520325C2 (fr)
DE2330338A1 (de) Okular-hypotensives mittel
DE202012005650U1 (de) Kombinationstherapeutikum für die Behandlung von Rhinitis
CH713095B1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Entzündungen.
DE102006061186A1 (de) Verwendung von Aluminium- und Chlor-haltigen Verbindungen zur äußerlichen Anwendung bei allergischen Hautreaktionen, Entzündungen, Juckreiz und/oder Schwellungen der Haut
DE102004008375B4 (de) Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege
DE202015104316U1 (de) Zusammensetzung für die Behandlung des Hals-/Rachenraums

Legal Events

Date Code Title Description
PUE Assignment

Owner name: BOYKA ANGELOV, CH

Free format text: FORMER OWNER: SCHWEIZER ZENTRUM FUER WISSENSCHAFTLICHE FORSCHUNG, INNOVATION UND ENTWICKLUNG, CH